{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resectable+Intrahepatic+Cholangiocarcinoma", "query": { "condition": "Resectable Intrahepatic Cholangiocarcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resectable+Intrahepatic+Cholangiocarcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T06:33:15.917Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05967182", "title": "A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholangiocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-01-16", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05967182" }, { "nct_id": "NCT05655949", "title": "Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bile Duct Cancer", "Cholangiocarcinoma", "Cholangiocarcinoma Non-resectable", "Cholangiocarcinoma Metastatic", "Metastatic Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Yttrium-90", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-13", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05655949" }, { "nct_id": "NCT07639528", "title": "Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Futibatinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2027-12-10", "completion_date": "2031-12-10", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07639528" }, { "nct_id": "NCT01525069", "title": "Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma", "Liver Neoplasms" ], "interventions": [ { "name": "Floxuridine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2012-04-03", "completion_date": "2022-08-02", "has_results": false, "last_update_posted_date": "2022-08-10", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525069" }, { "nct_id": "NCT06050252", "title": "Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-07-10", "completion_date": "2027-02-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 58, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 48 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Derby", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06050252" }, { "nct_id": "NCT03823144", "title": "Intravital Microscopy in Human Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Solid Tumor, Adult", "Clinical Stage IV Gastric Cancer AJCC v8", "Malignant Solid Neoplasm", "Metastatic Colorectal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Primary Malignant Brain Neoplasm", "Metastatic Sarcoma", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Resectable Colorectal Carcinoma", "Resectable Liver and Intrahepatic Bile Duct Carcinoma", "Resectable Pancreatic Carcinoma", "Resectable Sarcoma", "Stage IV Colorectal Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Malignant Brain Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Pancreatic Carcinoma", "Resectable Brain Neoplasm", "Resectable Breast Carcinoma", "Resectable Gastric Carcinoma", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Diagnostic Microscopy", "type": "DEVICE" }, { "name": "Fluorescein Sodium Injection", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-02-28", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03823144" }, { "nct_id": "NCT03267940", "title": "Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma Non-resectable", "Cholangiocarcinoma, Intrahepatic", "Cholangiocarcinoma, Extrahepatic", "Gallbladder Adenocarcinoma" ], "interventions": [ { "name": "PEGPH20", "type": "DRUG" }, { "name": "CIS", "type": "DRUG" }, { "name": "GEM", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2017-10-02", "completion_date": "2019-11-11", "has_results": true, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03267940" }, { "nct_id": "NCT03579771", "title": "Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Cholangiocarcinoma", "Stage IB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage II Intrahepatic Cholangiocarcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 30, "start_date": "2018-09-26", "completion_date": "2023-09-16", "has_results": true, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Rochester, Minnesota • Portland, Oregon + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03579771" }, { "nct_id": "NCT03377179", "title": "A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholangiocarcinoma", "Cholangiocarcinoma Non-resectable", "Cholangiocarcinoma, Perihilar", "Cholangiocarcinoma, Extrahepatic", "Cholangiocarcinoma, Intrahepatic" ], "interventions": [ { "name": "ABC294640", "type": "DRUG" }, { "name": "Hydroxychloroquine Sulfate 200 MG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RedHill Biopharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2018-03-07", "completion_date": "2022-06-21", "has_results": false, "last_update_posted_date": "2025-07-23", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03377179" }, { "nct_id": "NCT06381648", "title": "Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cholangiocarcinoma", "Cholangiocarcinoma, Intrahepatic", "Cholangiocarcinoma Resectable", "Cholangiocarcinoma; Liver" ], "interventions": [ { "name": "LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2023-04-15", "completion_date": "2025-07-01", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-06-26T06:33:15.917Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06381648" } ] }